The demand for treatments for hyposexual desire disorders is increasing, due to the high prevalence of lifestyle disorders such as stress and depression.

PORTLAND, OR, UNITED STATES, September 27, 2021 /EINPresswire.com/ – Hypoactive Sexual Desire Disorder (HSDD) is the most common sexual disorder in women of all ages, but it is also one of the most difficult disorders to treat. It is the most common type of sexual dysfunction in women. HSDD is primarily associated with hyperfunctional inhibition and hypofunctional excitation regulated by neuromodulators in the brain. In addition, several physical conditions are also linked to HSDD, including anxiety, depression, diabetes, urinary incontinence, and multiple sclerosis. Its treatment includes psychotherapy or drug therapy. Psychotherapy uses cognitive behavioral therapy, which offers counseling sessions with a sex therapist, while pharmacotherapy includes treatment with many drugs, namely buspirone, bremelanotide, bupropion, flibanserin and others.

The LATAM Female Hypoactive Sexual Desire Disorder Treatment market size was $ 131 million in 2019 and is expected to reach $ 170 million by 2027, registering a CAGR of 3.8% from 2020 to 2027.

Download a free sample report @ https://www.alliedmarketresearch.com/request-sample/7952

Impact Analysis of COVID-19 on the Hypoactive Sexual Desire Disorder (HSDD) Treatment Market LATAM

The lockdowns have had a negative impact on all types of businesses in Latin America. For example, non-essential businesses such as retail businesses that operate with a physical location with public access have been closed. In addition, non-essential constructions were also halted, leisure and entertainment businesses such as gymnasiums, cinemas, art centers, racetracks, salons and public and private social clubs were also closed under the lock. However, essential businesses such as grocery stores, pharmacies, hospitals, veterinary hospitals remained functional during the closures. In addition, the impact of COVID-19 on the LATAM female hypoactive sexual desire disorder treatment market has been quite negative, owing to the decline in demand and supply of drugs used in treatment. In addition, other factors that were responsible for a negative impact on the market included the limited availability of medical care, the shortage of healthcare personnel and the increasing burden of hospitalizations related to COVID-19. However, various governments are working to ensure an uninterrupted supply of drugs, which is expected to stabilize the market over time.

The LATAM Female Hypoactive Sexual Desire Disorder (HSDD) Treatment Market is expected to witness significant growth during the forecast period, owing to the increasing prevalence of lifestyle disorders, such as stress , depression, anxiety, prolonged fatigue, and increased use of drugs that induce hypoactive sexual desire disorder. In addition, the increase in the number of surgeries resulting in sexual dysfunction is also expected to drive the growth of the LATAM Female Hypoactive Sexual Desire Disorder Treatment market during the forecast period. However, the lack of awareness related to hypoactive sexual desire disorder is expected to hamper the growth of the market during the forecast period. The presence of solid pipeline products that show up in the late stages of clinical trials should be approved for commercialization in the coming years. Therefore, the presence of pipeline drugs provides a lucrative opportunity for the market for the treatment of hypoactive sexual desire disorders in LATAM women.

For a purchase request @ https://www.alliedmarketresearch.com/purchase-enquiry/7952

The LATAM Female Hypoactive Sexual Desire Disorder (HSDD) Treatment market is segmented on the basis of type, sales channel, and country. By type the market is categorized into buspirone and bupropion. Based on sales channels, it is divided into hospitals, clinics, and online retailers. As for countries, it is ranked in Brazil, Argentina, Chile, Colombia, Ecuador, Peru and the rest of LATAM.

By Type, the LATAM Hypoactive Sexual Desire Disorder Treatment market is segmented into Buspirone and Bupropion. The buspirone segment is expected to show the fastest growth rate during the forecast period, due to the fact that it is an FDA approved treatment for HSDD in premenopausal women, which makes it a preferred brand compared to off-label treatments. In addition, this type of treatment has fewer side effects than other treatment options on the market.

At the country level, Argentina is expected to show the fastest growth during the forecast period. This is attributed to factors such as increased healthcare infrastructure, increased healthcare spending, and awareness of hypoactive sexual desire disorder.

Access the full report @ https://www.alliedmarketresearch.com/latam-hypoactive-sexual-desire-disorder-treatment-market-A07587

The main key players are:

Aurobindo Pharma, Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Mylan NV, Novartis AG, Palatin Technologies, Inc., Sprout Pharmaceuticals, Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd. and Zydus Cadila.

Main conclusions of the study:

• By treatment type, in terms of value, the bupropion segment dominated the market in 2019 and is expected to maintain its dominance throughout the forecast period.
• By sales channel, the clinic segment is expected to grow with the highest CAGR throughout the forecast period.
• By type of treatment, the bupropion segment represented more than half of the market share in 2019.
• By country, Argentina is expected to experience the highest growth during the analysis period.

Health Industry Trend Reports:

Diagnostic Electrocardiograph (ECG) Market Analysis, Industry Forecast 2030

Digital Printing Systems Market Analysis, Industry Forecast, 2030

Dipeptidyl Peptidase-4 (DPP-4) Inhibitors Market Industry Forecast, 2030

About Us:

Allied Market Research (AMR) is a full-service market research and business consulting arm of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global businesses as well as medium and small businesses with unmatched quality of “market research reports” and “business intelligence solutions”. AMR has a focused vision to provide business information and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.

David Corréa
Allied Analytics srl
+1 503-894-6022
write us here
Visit us on social networks:
Facebook
Twitter
LinkedIn